A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. Adnexus MAbs. 2011 [ISPRI prediction of immunogenicity]
Recent Posts
- EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services   Â
- Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
- EpiVax Enters its Next Chapter with SV Health Investors
- Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
- Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
Recent Comments
No comments to show.